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Glycine receptors (GlyR) belong to the pentameric ligand-
gated ion channel (pLGIC) superfamily and mediate fast inhib-
itory transmission in the vertebrate CNS. Disruption of glycin-
ergic transmission by inherited mutations produces startle
disease inman.Many startlemutations are inGlyRs and provide
useful clues to the function of the channel domains. E103K is
one of few startle mutations found in the extracellular agonist
binding site of the channel, in loop A of the principal side of the
subunit interface.Homologymodeling shows that the side chain
of Glu-103 is close to that of Arg-131, in loop E of the comple-
mentary side of the binding site, and may form a salt bridge at
the back of the binding site, constraining its size. We investi-
gated this hypothesis in recombinant human 1 GlyR by site-
directed mutagenesis and functional measurements of ago-
nist efficacy and potency by whole cell patch clamp and single
channel recording. Despite its position near the binding site,
E103K causes hyperekplexia by impairing the efficacy of gly-
cine, its ability to gate the channel once bound, which is very
high in wild type GlyR.Mutating Glu-103 andArg-131 caused
various degrees of loss-of-function in the action of glycine,
whereas mutations in Arg-131 enhanced the efficacy of the
slightly bigger partial agonist sarcosine (N-methylglycine).
The effects of the single charge-swapping mutations of these
two residues were largely rescued in the double mutant, sup-
porting the possibility that they interact via a salt bridge that
normally constrains the efficacy of larger agonist molecules.
Ion channels that belong to the pentameric ligand-gated
superfamily (pLGIC)5 are found both in prokaryotic and eu-
karyotic organisms. In vertebrates, including man, pLGIC me-
diate fast synaptic transmission both in the periphery (see for
instance, the cation permeable, nicotinic ACh receptors at the
neuromuscular junction) and in the central nervous system (cf.
the inhibitory, anion-permeable GABA and glycine receptors).
pLGIC are activated by the binding of agonist/neurotransmit-
ters to canonical binding sites at the extracellular interface of
two subunits. Each receptor type recognizes as agonists a fairly
narrow range of ligand molecules. However, in the superfamily
as a whole, the group of chemical structures that can activate
these channels is remarkably diverse, from small amines such as
ACh or propylamine, to amino acids (glycine, GABA, and glu-
tamate), to aromatic compounds (histamine, serotonin, tyra-
mine, and nicotine). How pLGIC achieve this level of agonist
recognition is still an area of intense investigation (1).
Structural data from several pLGIC members show that
channel subunits have a conserved fold and that themain struc-
tural features of the agonist binding site, as first hypothesized in
the early 1990s (2), are shared across the superfamily. Thus, the
site is made by “loops” A, B, and C from the outer  sheet of the
anticlockwise (principal) subunit and by loops D to G from
the inner  sheet of the clockwise (complementary) subunit.
The loops contain many aromatic residues, an “aromatic box”
(3, 4) whose side chains form cation- interactions with the
positively charged moiety of pLGIC agonists. The actual aro-
matic residues that make the “box” differ across pLGIC sub-
types, and probably so does the size of the aromatic box (5).
Combining structural and functional data with homology
modeling suggests that few of the loop residues form direct
bonds with the agonist, whereas others contribute to holding
these key residues in place (1, 6, 7). Which agonists are recog-
nized and what sets their efficacy is likely to be influenced by
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other properties of the binding site, such as its size and flexibil-
ity both at rest and after activation, but we do not know how
these are determined in the protein.
For pLGICs as for other channels, important clues about the
function of the different structural domains have come from
the discovery and characterization of channelopathymutations
that cause inherited disease in man. The human disease associ-
ated with impaired glycinergic transmission is called startle
disease or hyperekplexia, and is caused most often by loss-
of-function mutations of glycine receptors (GlyR), particularly
in the 1 subunit (8). Startle disease mutations are thought to
exert their effects largely by damaging receptor gating, namely
how well the GlyR opens once it has bound the neurotransmit-
ter glycine (9, 10). This hypothesis is largely based on the anal-
ysis of the first mutations to be characterized, such as K276E
and Q266H (9–12). These residues are in the transmembrane
domain of the channel, where the channel gate is and where
most startle mutations are found. Relatively few startle muta-
tions are in the receptor binding site and little is known of how
they may act. If these disrupt binding, anything short of a pro-
found disruption of agonist binding is unlikely to damage gly-
cinergic synaptic transmission enough to produce a startle
phenotype, because glycine in the synaptic cleft reaches high
concentrations of 2.2–3.5 mM (13) and this should provide a
safety margin. A recent report (14) has shown that a startle
mutation lethal in themouse, N46K1GlyR (near the principal
side of the binding site) may exert its effects by speeding up
GlyR deactivation. Startle mutations that are in the binding site
and do not abolish agonist bindingmay be particularly interest-
ing to investigate, as they are likely to act by interfering with the
transduction of the agonist binding signal toward the pore. This
“gating aspect” of the binding site function is poorly under-
stood, but important, as it must contribute to how agonist effi-
cacy is determined.
The startlemutation E103K in loopA, on the principal side of
the binding pocket (Fig. 1, A and B), was first described in a
patient whose second 1 allele carried a frameshift mutation
(15). Our homology model of the GlyR (7) based on the struc-
ture of GluCl (16) suggested that the side chain of Glu-103 is
likely to form a salt bridge across the binding site with Arg-131
in loop E of the complementary subunit. To our knowledge,
no hyperekplexia mutations have been reported for Arg-131.
Molecular dynamics simulations on a new model built on the
recent cryo-EM structure of the zebrafish1GlyR (17) confirm
that the salt bridge is present and show that it is conformation-
ally stable (at least on a 500-ns time scale). In the present study
we confirmed the interaction between these two residues and
found that, despite its binding site location, the hyperekplexia
E103K mutation affected only glycine efficacy. The effect of
mutatingGlu-103 andArg-131was different for the full agonist
glycine and the bulkier, partial agonist sarcosine.
Results
The Hyperekplexia Mutation E103K Decreases Both the
Potency and the Efficacy of Glycine on 1 GlyR—Fig. 1A shows
the position of the Glu-103 residue in a view taken from the
GlyR homology model (7) that we produced (cyan) from the
structure of GluCl (34% sequence identity with the 1 GlyR
(16). Glu-103 is located at (or near) loop A of the principal ()
subunit (on the left in Fig. 1A, orange in Fig. 1C), and its nega-
tively charged side chain is near the positively charged side
chain of Arg-131 in loop E on the complementary () side of
the binding site (on the right in Fig. 1A, purple in Fig. 1C). In the
model, distances between side chain hydrogen atoms of Arg-
131 to the side chain oxygen atoms of Glu-103 are 2.52.8 Å, a
range compatible with the presence of a salt bridge, which con-
ceivably might have a stabilizing effect both on loops A and E
and tighten the size of the binding site. The homology model is
very similar to the structure of the zebrafish 1 GlyR (green in
Fig. 1A; Protein Data Bank (PDB) code 3JAE) (17), where the
position of the side chains of the two amino acids is not well
defined. To investigate this further we performed molecular
dynamics simulations (500 ns each for glycine and sarcosine
bound) on a new model of human 1 GlyR based upon
the zebrafish 1 GlyR structure (with glycine bound; PDB code
3JAE) (17); the domains in the structure have 94% sequence
identity with the human 1 GlyR). In both cases the salt bridge
was conformationally stable and present for at least 90% of
the simulation time (90% for glycine bound and 97% for sarco-
sine) as averaged for all five binding pockets. The binding
modes and salt bridge behavior were similar for glycine and
sarcosine (Fig. 1C, left and right).
Glu-103 and Arg-131 are at the back of the binding site,
toward the extracellular vestibule of the pore. Glu-103 is adja-
cent to residue Lys-104, whose charged side chain is likely to
be exposed to the pore vestibule, and is one of the conduct-
ance determinants in pLGIC channels (18, 19). In our model,
the charged side chains of both Glu-103 and Arg-131 are far
from the center of the pore, at a distance of 16 Å, and are
not exposed to the interior of the pore. Thus, it is unlikely
that Glu-103 and Arg-131 affect conductance directly, but
we cannot exclude that mutating either residue may change
conductance by perturbing the position of nearby residue
Lys-104.
Interestingly, both the GluCl and the zebrafish homology
models show that Glu-103 and Arg-131 residues are also at
some distance from the agonist (8 Å from glycine for exam-
ple; data not shown), and thus any direct interaction with the
agonist is expected to beminor aswell. Any effects are therefore
likely to be indirect, and to be exerted by affecting other resi-
dues, which do form direct bonds with glycine, such as loop A
Phe-99 or loop E Ser-129. The salt bridge between Glu-103 and
Arg-131might be needed tomaintain the correct conformation
of loop A, which in turn influences the direct bonds of other
residues with the agonist. An alignment of the amino acid se-
quences in loops A and E of nine pLGIC channels is shown in
Fig. 1B. The Glu/Arg pair of residues in these locations are
conserved in a subset of the inhibitory pLGIC receptors, namely
all the GlyR subunits (1–4 and ), irrespective of species, in
Caenorhabditis elegansGluCl and in a fewGABA receptor sub-
units, but is absent in the cationic channels (nicotinic, 5-HT3,
GLIC, and ELIC).
In light of our considerations from the homology models,
and our hypothesis that a salt bridge betweenGlu-103 andArg-
131 stabilizes loops A and E and tightens the binding site, we
decided to test the effects of the E103K startle mutation on the
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GlyR responses to the full agonist glycine and to the partial
agonist sarcosine (20). Sarcosine (N-methylglycine) is slightly
bulkier than glycine (see the structures of the two agonists in
Fig. 1C) because of the methyl group substitution on the amino
group, which is likely to be oriented toward the back of the
binding site (7).
FIGURE 1.Homologymodeling reveals a salt-bridge between residues Glu-103 and Arg-131. A, location of the Glu103-Arg131 salt-bridge as predicted by
a GlyR homology model (cyan)(7) built using GluCl as template (PDB code 2XYS) (16). The model is overlaid with the recent cryo-EM structure (green) of the
zebrafish1GlyR (PDB 3JAE) (17). Note that the Glu-103 side chain is not fully resolved in the cryo-EM structure, but is certainly within distance to form the salt
bridge as postulatedby themodel.B, an amino acid alignment of this region for ninemembers of thepLGIC superfamily showing thepositionof the salt bridge
between Glu-103 (red) and Arg-131 (blue) and its conservation in glycine receptors. Other conserved positions are indicated by a gray background. C, the
agonist bindingmode and the Glu103-Arg131 salt bridge in a GlyR homologymodel based on the zebrafish 1 GlyR structure (PDB 3JAE) (17). Glycine (left) and
sarcosine (right) are shown in the final frame after 500 ns simulation time. Orange, principal subunit; purple, complementary subunit. For both ligands, the
carboxyl group is sandwiched by hydrogen bonds with Thr-204 and Ser-129 and is further stabilized by a salt bridge with Arg-65. The ammonium moiety
interacts with a water molecule in the binding pocket, and the water is stabilized by hydrogen bonds to Glu-157 and to the backbone carbonyl oxygen of
Ser-158 (as in Ref. 7). The ammonium group of glycine engages in an additional cation- interaction with Phe-207 and forms a hydrogen bond with the
backbone carbonyl group of Phe-159. This is sterically hindered for sarcosine by its additional N-methyl group.
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We began our investigation by obtaining whole cell concen-
tration-response curves from HEK 293 cells expressing homo-
meric GlyR. Fig. 2A shows typical currents responses for the
wild type 1 GlyR (top two panels) and the E103Kmutant (bot-
tompanel) to the agonists glycine and sarcosine.Glycine is a full
agonist on homomeric 1 GlyR (21), but the traces in Fig. 2A
(middle panel) show that sarcosine is a partial agonist, and its
maximum current responses reach only 80% of those to glycine
when the agonists are applied to the same cell at saturating
concentrations (10 mM for glycine and 100 mM for sarcosine;
Table 1). The time course of the currents was similar for both
agonists, and desensitization became apparent at EC30-EC50 for
both glycine and sarcosine on WT and mutant receptors.
The E103K mutation reduced the channel sensitivity to ago-
nists. The effect was relatively small for glycine, whose EC50
increased from 0.23  0.02 to 0.71  0.11 mM (n  10 and 3,
respectively; Fig. 2A, filled andhollow circles in Fig. 2C; Table 1).
The loss of potency of sarcosine was much greater. In the
mutant this prevented us from obtaining a full sarcosine
dose-response curve (because of the very high concentra-
tions required to saturate the curve). Thus we could not
establish whether the mutation changed the sarcosine max-
imum response relative to glycine. Such a decrease in the rela-
tive maximum response to a partial agonist would have been
the simplest way to check whether this binding site mutation
impairs channel gating.
An even betterway to assesswhether amutation has an effect
on gating is tomeasure the channel maximumopen probability
in single channel records. The measurement of cluster open
probability has the advantage (versus whole cell macroscopic
responses curves) of measuring an absolute open probability
value that is not affected by the level of expression of the differ-
ent channels examined or by changes in the channel conduct-
ance produced by the mutations. In addition, cluster open
probability measures only changes in receptor activation and is
not affected by desensitization (as desensitized intervals are not
included in the analysis). Because of that, in Fig. 2C (and the
following figures) we display concentration-response curves
as whole cell responses scaled to the maximum open probabil-
ity measured by single channel analysis.
The traces in Fig. 2B show clusters of single channel activity
in cell-attached patches at saturating agonist concentrations.
The glycine traces (top) show that the channel exposed to 10
mM glycine is practically either desensitized or open all the
time, with a very highmaximum Popen of 0.987 0.002 (n 49
clusters from 9 patches; measured as cluster open time/total
cluster time), confirming that glycine is a very efficacious ago-
nist onWThomomericGlyR (21). In agreement with thewhole
cell data, single-channel WT clusters activated by a saturating
sarcosine concentration (100 mM; Fig. 2B,middle trace) have a
lower maximum Popen of 0.70  0.03 (n  22) and therefore
confirm that sarcosine is a partial agonist in WT GlyR. The
bottom trace of Fig. 2B shows channel activity evoked by glycine
in the E103K mutant. These openings show that the mutation
did not affect conductance, as their amplitude is similar to that
of WT channels (right-hand column in Table 1). Mutating the
adjacent residue Lys-104 to glutamate produces a 22% conduct-
ance decrease in the 1 homomeric GlyR, but Lys-104 is likely
to be exposed to the channel pore (18). Mutant channel activity
showed distinct clustering, with an open probability of 0.73 
FIGURE 2. The E103K startle mutation reduces the sensitivity of 1 GlyR to both glycine and sarcosine and impairs channel gating. A, representative
whole-cell current responses evoked by U-tube agonist application to HEK 293 cells expressing WT 1 GlyR (upper panels, 2 different cells) or E103K 1 GlyR
(lower panel, 2 different cells). Black bars above the traces show the timing of the applications. Panels also show the responses to a saturating concentration of
glycine obtained in the cells used for the sarcosine concentration-response curves. B, clusters of single channel activity elicited by saturating concentrations of
glycine (upper panel) or sarcosine (middle panel) on WT 1 GlyR or (glycine only) on E103K GlyR (lower panel; cell-attached configuration, channel openings
downwards). Note the decreased single channel Popen in mutant receptors. C, whole cell concentration-response curves to glycine and sarcosine inWT (n 7
and 10, respectively) and E103K 1 GlyR (n 4 and 3, respectively). Curves are scaled to themaximum single channel Popen measured at saturating glycine or
sarcosine; for sarcosine on E103K GlyR, we could notmeasure themaximum single channel Popen and the curve is scaled indirectly (e.g. responses to sarcosine
are scaled to the macroscopic maximum response to glycine in the same cell, and then scaled to the maximum glycine single channel Popen).
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0.07 (n  13) to saturating glycine. Single-channel activity of
E103K mutants in response to 300 mM sarcosine was not
informative, not only because we do not know whether this
concentration produces maximum activation, but also because
clusters were sometimes hard to define unambiguously and
because there was substantial heterogeneity in the channel
open probability from cluster to cluster (data not shown).
Thus single channel data confirm that the E103K mutation
must impair channel gating elicited by the full agonist glycine.
Many mutations that produce loss of gating function have sim-
ilar effects on all agonists, but given the position of this muta-
tion is near the binding site, we investigated this further.
The Effect of Mutating Residues Glu-103 and Arg-131 on the
Agonist Action of Glycine and Sarcosine Is Different—To test
the hypothesis that there is a salt bridge between Glu-103 and
Arg-131, we mutated both residues individually to an alanine
and also reversed the side chain charges, to arginine and gluta-
mate, respectively.
Fig. 3 shows the effects of mutating either residue on re-
sponses to the full agonist glycine. Traces in panel A show that
the time course of agonist responses was not affected by the
mutations. There was a clear pattern of effects on the activity of
glycine: shortening the residue side chain and removing its
charge by replacing glutamate or argininewith alanine had only
negligible effects in either the 103 or 131 positions. This was
true for both the potency of glycine (Fig. 3C, Table 1) and for its
efficacy, as both the E103A and R131A mutants maintained a
high maximum Popen (0.97 0.01 and 0.95 0.01, n 11 and
16, respectively; top traces in Fig. 3B; Table 1).
The picture was different when the side chain charge was
reversed. In R131E therewas a substantial decrease in the chan-
nel sensitivity to glycine (to an EC50 of 1.6  0.2 mM, n  4;
Table 1) accompanied by a small decrease in maximum Popen
(to 0.93  0.02). A more marked effect was seen with E103R,
where the increase in EC50 (to 1.4 0.4mM, n 8; Table 1) was
associated with a clear reduction in the slope of the dose-re-
sponse curve (from 1.58  0.07 to 0.78  0.03), an effect not
seen with E103K. At 200 mM glycine, a concentration that
should bemaximal on the dose-response curve, the single chan-
nel Popen of E103R was 0.87  0.02 (cf. 0.987 and 0.73 for WT
and E103K, respectively; Table 1).
Fig. 4 shows that with the bulkier partial agonist sarcosine,
the effect of the mutations depended mostly on their location.
Mutating Glu-103 had only a small impact for both E103A and
E103R. Thus we observed no shift, or a modest one, in macro-
scopic EC50 and no clear change in maximum Popen (left panels
in Fig. 4B; 0.70  0.03, 0.67  0.08, and 0.79  0.03 for WT,
E103A, and E103R, respectively; n 22, 8, and 31 clusters). In
contrast with that, both mutations of Arg-131 markedly
increased the Popen of sarcosine-evoked clusters (right-hand
panels in Fig. 4B) and turned sarcosine into a nearly full agonist.
For the R131A mutation, the increase in maximum Popen
(0.95 0.04, n 37) was associated with an increase in sarco-
sine potency, and the EC50 shifted from 14 mM (WT) to 4.5 
0.5 mM (Table 1; n 7 and 5).
For R131E, we cannot be sure that the concentration-re-
sponse curve is reaching its maximum at the highest concen-
tration of sarcosine that we could test (300 mM). Nevertheless,
this concentration elicited a Popen of 0.91 ( 0.04; n  21; cf.
bottom left trace of Fig. 4B), higher than the WT maximum
value. Equally, the EC50 in the mutant must be greater than 75
mM, and therefore sarcosine potency was decreased by at least
5-fold. Note that enhanced gating (proven by the increase in
Popen in these mutants) per se should increase the potency of
an agonist. As enhanced gating was accompanied instead by a
sizeable decrease in potency, the R131E mutation must also
decrease sarcosine affinity for the resting receptor.
Reversing the Side Chain Charges on Both Glu-103 and Arg-
131: the Effect of the Double E103R/R131E Mutation on the
Agonist Action of Glycine and Sarcosine—Fig. 5C (left panel)
shows that the double E103R/R131E mutation substantially
rescued the effects on receptor function of the single charge
reversal mutants. This was particularly clear in the case of gly-
cine, with an EC50 in the double charge reversal mutant of
0.43 0.04 mM (black circles, n 5), close to the WT value of
0.23 mM (Fig. 5, A and C; cf. an EC50 of 1.4 0.4 mM for E103R
and 1.6 0.2mM for R131E; shown as dashed and dotted curves
in Fig. 5C; Table 1). The cluster single channel trace in Fig. 5B,
TABLE 1
Properties of wild type andmutant human recombinant 1 GlyR in patch clamp experiments
Whole cell dose-response curves Single channel measurements
EC50 Imax Imax/IGLY max nH n Concentration
maxPopen
(# clusters) Amplitude n
mM nA mM pA
Glycine
WT 0.23 0.02 8 2 1.58 0.07 10 10 0.987 0.002 (49) 5.2 0.2 9
E103K 0.71 0.11 2.7 1.4 1.32 0.06 3 50 0.73 0.07 (13) 5.2 0.1 3
E103A 0.43 0.05 5.9 0.3 1.24 0.06 3 100 0.97 0.01 (11) 5.6 0.2 3
E103R 1.4 0.4 12.8 1.6 0.78 0.03 8 200 0.87 0.02 (11) 5.8 0.1 3
R131A 0.19 0.03 8.7 1.9 0.90 0.01 5 30 0.95 0.01 (16) 4.58 0.04 2
R131E 1.6 0.2 1.5 0.3 1.6 0.1 4 50 0.93 0.02 (28) 3.90 0.03 2
R131E/E103R 0.43 0.04 3.7 0.4 0.95 0.02 5 100 0.996 0.001 (9) 4.8 0.1 5
Sarcosine
WT 14 1 5.1 0.6 0.80 0.03 1.51 0.04 7 100 0.70 0.03 (22) 5.6 0.3 4
E103K 80 1.5 0.4 0.62 0.04 1.37 0.03 4 300 Very heterogeneous 4.2 0.1 8
E103A 23 3 5.1 1.7 0.76 0.03 1.8 0.2 4 100 0.67 0.08 (8) 4.5 0.4 4
E103R 17 3 2.6 0.8 0.84 0.09 1.22 0.05 5 200 0.79 0.03 (31) 5.0 0.1 4
R131A 4.5 0.5 6.0 1.1 0.93 0.02 1.4 0.1 5 100 0.95 0.01 (37) 5.4 0.1 3
R131E 75 2 6.6 0.9 0.81 0.03 2.05 0.03 6 300 0.91 0.04 (21) 4.7 0.1 2
R131E/E103R 15 2 8.1 2.3 0.95 0.04 1.28 0.07 8 100 0.97 0.01 (23) 4.9 0.3 8
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top, shows that the maximum Popen elicited by glycine in the
doublemutant is also similar to that ofWTGlyR (0.996 0.001
and 0.987 0.002, n 9 and 49, respectively).
The picture is slightly different for sarcosine.Here the double
mutant has a sarcosine EC50 (Fig. 5,A andC) very similar to that
ofWT receptors (15 2 and 14 1 mM for the double mutant
and wild type, respectively; cf. 17 3mM for E103R and at least
75 2mM for R131E).However, themaximumPopen elicited by
sarcosine in the doublemutant has remained high (0.97 0.01)
and resembles more the reverse charge mutant R131E (where
the maximum Popen is at least 0.91 0.04) than it does theWT
receptor (0.70 0.03). Thus,most of the effects of single charge
reversal mutations of these residues are rescued by swapping
their side chains, supporting the hypothesis that they form an
intersubunit salt bridge.
Discussion
Our main finding is that residues Glu-103 in loop A and
Arg-131 in loop E of the canonical GlyR agonist binding site are
important determinants of agonist gating efficacy, and that
their influence is agonist-dependent.
The Startle Disease Mutation E103K in Loop A of the Agonist
Binding Site Acts by Impairing Glycine Gating—This mutation
reduced the efficacy of the full agonist glycine on human 1
GlyR, as it decreased the maximum Popen produced by the
amino acid from 0.987 to 0.73. This effect was associated with a
relatively small loss in glycine potency, which brought the gly-
cine EC50 from 0.23 to 0.71 mM. This loss in potency can be
entirely accounted for by the reduction in glycine efficacy. The
reason is as follows. The maximum Popen measured in a single
channel cluster depends only on effective efficacy Eeff (defined
as in Ref. 22, as EF/(EF F 1), where E is the opening equi-
librium constant and F is the equilibrium constant for the pre-
opening flip conformational change). Maximum Popen  Eeff/
(Eeff  1). Our Popen data imply a decrease in Eeff of 20–25-
fold (from 70 in WT receptors to 3 in the E103K GlyR). We
know that the GlyR requires three molecules of agonist to open
effectively (21) and we can therefore estimate that the 20-fold
reduction in efficacy observed for E103K should by itself
increase agonist EC50 by3-fold (the cube root of 20) (23). This
shift in EC50 is close to the onewe observed in our experiments,
and suggests that the E103K mutation does not cause major
changes in the affinity of glycine for the binding site in its rest-
ing state.
This is in line with the structural information that Glu-103
does not contact the glycine molecule directly, and makes this
residue particularly interesting, as it is a strong gating determi-
nant for glycine, despite its position in the binding site. Differ-
ences in efficacy are translated into differences in gating, and
reflect how much different agonists stabilize the active form of
the channel. In pLGIC this is determined by the initial confor-
mational changes and pre-open intermediate states (flip/
primed/catch-and-hold) (22, 24–26). At the binding site, effi-
FIGURE 3. Reversing the side chain charge in positions Glu-103 or Arg-131 changes the potency and efficacy of glycine. A, representative whole cell
current responses to glycine applied to GlyR 1 mutants. B, clusters of single-channel mutant GlyR activity elicited in cell-attached patches by saturating
concentrations of glycine.C,whole cell concentration-response curves for the effect of glycineonE103A, E103R, R131A, andR131EmutantGlyR (n3, 8, 5, and
4, respectively). Curves are scaled to themaximum Popen obtained from single channel recordings. TheWT concentration-response curve for glycine is shown
for comparison (solid line; the data for this curve is shown in Fig. 2C).
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FIGURE5.E103R/R131Emutation rescues1GlyR response toglycineandsarcosine.A, representativewhole cell current responses toglycineor sarcosine
in the double charge reversal mutant E103R/R131E GlyR 1. B, clusters of single-channel mutant GlyR activity elicited in cell-attached patches by saturating
concentrations of glycine and sarcosine, respectively. C, glycine and sarcosine whole cell concentration-response curves in WT and double mutant GlyR (n
5 and 8, respectively). Curves are scaled to the appropriatemaximum Popenmeasured by single channel recording. TheWT concentration-response curves and
the single-mutation curves for both glycine and sarcosine are shown for comparison (solid line for WT; the data for this curve is shown in Fig. 2C).
FIGURE 4. Removing or reversing the side chain charge of Arg-131 increases the efficacy of the partial agonist sarcosine on1 GlyR. A, representative
whole cell current responses to sarcosine in 1 GlyR mutants. B, clusters of single-channel mutant GlyR activity elicited in cell-attached patches by high
concentrations of sarcosine (saturating except for the R131E mutant) C, sarcosine whole cell concentration-response curves for E103A, E103R, R131A, and
R131E mutant GlyR (n  4, 4, 5, and 6, respectively). Curves are scaled to the appropriate maximum Popen measured by single channel recording. The WT
concentration-response curve for sarcosine is shown for comparison (solid line; the data for this curve is shown in Fig. 2C).
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cacy is reflected by the increase in microscopic affinity for the
agonist as the channel enters the pre-open intermediate state.
Our data suggest that E103Kmust reduce this affinity increase,
while leaving the basal affinity (for the resting state) un-
changed. A great deal more molecular dynamics simulation
data with the two agonists will be required to clarify how this
effect maps to structure and the binding domain changes with
activation. Further probing the role of this residuewith conven-
tional mutagenesis is limited by the restricted range of replace-
ment side chains that can be introduced. Nevertheless, we
found that mutating this residue to Arg instead of Lys had a
much greater effect on glycine potency, with at least a 16-fold
decrease. This effect is no longer purely on gating, but must
impair also resting binding affinity, perhaps because the great-
er bulk of the positively charged side chain of Arg versus Lys
causes some repacking. Employing unnatural amino acid mu-
tagenesis to produce subtler side chain changes is likely to be
needed.
Thus, despite its position in the binding site, startle disease
mutation E103K acts by affecting channel gating, in line with
other GlyR channelopathy mutations whose mechanism has
been analyzed, such as K276E, A52S, and Q266H (10–12, 27),
with the exception of N46K (14). We can estimate roughly the
effects of E103Kon a glycinergic synaptic current by calculating
the time course and open probability of the channel in response
to a synaptic glycine pulse (13). We used the rate constants in
themechanismwe established for homomeric1GlyR (28) and
reduced the forward rate constants of the initial conformational
changes so that the mechanism reproduces the properties of
E103K we observed here. We found that the main effect of the
mutation is a substantial reduction in current amplitude, with a
drop in peak Popen from 0.73 to 0.13. Our calculations were
done for a homomeric GlyR, and synaptic GlyR are heteromers,
but it is reasonable to assume that in heteromers we would see
a similar functional impairment, perhapsmitigated by the pres-
ence of the WT  subunit.
Mutating ResiduesGlu-103 andArg-131HasDifferent Effects
on Glycine and Sarcosine—Our single channel recordings gave
direct measurements of agonist efficacy, but we found that the
pattern of effects on the two agonists of the five single muta-
tions and the double mutation was quite complex and hard to
interpret in its entirety.
For glycine, charge reversal mutations produced loss-of-
function phenotypes, which were somewhat different for Glu-
103 and Arg-131. E103K produced a major decrease in glycine
maximum Popen which, as discussed above, was not accompa-
nied by detectable changes in affinity. Glycine is a very effica-
cious agonist onGlyR, with an Eeff of 70, and thismakes it easier
to detect losses of efficacy than gains in efficacy. Arewe likely to
miss increases in glycine opening efficacy (cf. the ones observed
for sarcosine)? Given maximum Popen  Eeff/(Eeff 1), we
would expect to be able to detect decreases in glycine efficacy
greater than 4-fold. An increase in glycine efficacy cannot
change the maximum Popen, but should still be detectable,
because it is expected to increase the potency of glycine, as EC50
is inversely proportional to Eeff. The detection of such an effect
could nevertheless be confounded by concurrent changes inKd.
The situation is different for sarcosine. Sarcosine is a partial
agonist (Eeff about 2.5), and therefore its maximum Popen
should change clearly in response to both gain and loss of func-
tion mutations. For sarcosine, the effects of mutating Glu-103
were negligible for Ala or Arg mutations (Fig. 4C) and substan-
tial for the Lys mutation (Fig. 2c), which we could not charac-
terize completely because achieving saturating concentrations
becameosmotically impossible. Somewhat surprisingly, both of
the two mutations tested for Arg-131 enhanced sarcosine gat-
ing, but the two mutations had opposite effects on potency:
R131A increased sarcosine potency, but R131E decreased it,
implying that R131E must cause also a decrease in sarcosine
binding affinity. In contrast with that, R131E had produced a
small loss in both efficacy and affinity for glycine. The differ-
ences in the effects of Arg-131 mutations on glycine and sarco-
sine efficacy show that the determinants of efficacy are different
for the two agonists.
This is the first time that such different effects of a mutation
on two agonists has been documented at single channel level for
GlyR and shown to involve opposite changes in the efficacy of
the two agonists. Other positions in loop A of GlyRs (Lys-104,
Phe-108, and Thr-112) have beenmutated in oocyte-expressed
human 1 GlyR (29) in an alanine-scan and found to produce
gain of function, general or confined to a subset of the agonists.
These mutations are also likely to affect gating, as they in-
creased themaximumwhole cell response to the partial agonist
taurine (relative to glycine).
Is Glu-103 Forming a Salt Bridge with Arg-131?—Both our
homologymodel and the recent structural information onGlyR
are consistent with the possibility that the side chains of loop A
residue Glu-103 and loop E residue Arg-131 may form a salt
bridge at the back of the agonist binding site and our data on the
whole support the existence of this salt bridge.
The strongest evidence in favor comes from the double mu-
tant experiments, in which swapping the side chains of residues
Glu-103 and Arg-131 rescued most of the effects of the single
point mutations. The exception was the increase in sarcosine
efficacy seen with Arg-131 single mutations, which persisted in
the double mutant. We do not know why this is the case. In the
double mutant, the salt bridge may have the right length, but
the interacting charged moieties (guanidinium in Arg and car-
boxylate in glutamate) should be in a different position, and lie
closer to the complementary side of the site. Against the salt
bridge hypothesis is the finding that eliminating the charge on
either residue (by Ala mutations) had practically no effect on
the GlyR activation by glycine. In anymutant, it is possible that
the bond that we try to disrupt is replaced by a different
interaction, but we are entering the realms of speculation.
Our data show that it is not easy to understand the network of
interactions at the binding site even if we have unambiguous
measurements of efficacy by single channel recording and a
validated homologymodel. Exploring the salt bridge hypothesis
further will require extensivemolecular dynamics investigation
of the conformation of the binding pocket, and how its interac-
tions with different agonists change as the channel activates.
This will require a large amount of simulation that we have just
begun and which is beyond the scope of the current paper.
These investigations would then suggest additional functional
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experiments, which could include subtler residue changes with
unnatural mutagenesis, and the formation of covalent disulfide
bonds on activation.
Experimental Procedures
Homology Modeling—The human 1 GlyR model was con-
structed from the structure of Danio rerio 1 GlyR (glycine-
bound open state; PDB code 3JAE) (17). The protein sequences
for the two GlyRs (UniProt P23415 and O93430, respectively)
were aligned using Muscle (30) and edited manually. 100 mod-
els were created with MODELLER version 9.16 (31) and out of
the intersection of the top 10 of both DOPE score (32) and
molecular PDF (31) themodel with the bestQMEAN score (33)
was chosen for simulation. The termini of the model were
capped with N-terminal acetyl and C-terminal acetamide with
Maestro (Schrödinger Release 2013-2, Ref. 58) and hydrogens
were added to the protein with the pdb2gmx tool of Gromacs
5.1 (34), assigning all side chains a protonation state at physio-
logical pH (7.4).
Ligand Docking and Parameterization—The structures of
the ligands glycine and sarcosine were taken from the ZINC
ligand database (35). For each ligand and binding pocket, 50
bindingmodeswere generated on a spherical search space of 12
Å diameter centered on the aromatic boxwith the docking pro-
gramGold (36) and the best-ranked one of each was selected as
the final pose. The ligands were parameterized with AM1-BCC
charges (37) and parameters from the general Amber force field
(38) using ACPYPE (39).
System Set Up—Simulations were set up using a coarse-
grained approach with the Martini force field version 2.2 using
martinize (40) to coarse-grain the protein model. The overall
systems were set up in a hexagonal prism as the periodic simu-
lation box using insane (41), inserting the protein model in a
1-palmitoyl-2-oleoyl-sn-glycero-phosphocholine (POPC) bi-
layer, solvating in water, and adding sodium and chloride ions
to neutralize the net charge and simulate a physiological con-
centration of 150 mM. Gromacs 5.1.x (34) was used for energy
minimization and subsequent 500-ps constant temperature,
constant volume (NVT)-, and 1-s constant temperature, con-
stant pressure (NPT) equilibration. Simulation details were
based on the recommended new-rf.mdp parameters (42) and
appropriately adjusted. The final frame was then converted to
all-atom resolution via backward (43). The original all-atom
protein model was substituted into the system with the ligands
in the poses predicted by docking.
All Atom Molecular Dynamics (MD) Simulations—The en-
ergy minimization and dynamics simulations were per-
formed using Gromacs 5.1.x (34) and the following force fields:
AMBER99SB-ILDN (44) for protein and ions, TIP3P for water
(45), Slipids (46–48) for lipids, and the general Amber force
field (38) for the ligands. Periodic boundary conditions in all
three spatial dimensionswere applied. Each systemwas energy-
minimized using the steepest descent algorithm until the max-
imum force fell below 1000 kJmol1 nm1. During all phases of
equilibration, position restraints were applied to the protein
heavy atoms and all ligand atoms with a force constant of 1000
kJ mol1 nm2. 100 ps of NVT equilibration at 310 K were
followed by 30-ns NPT equilibration at 1 bar. Production runs
were run with no restraints for 500 ns in the NPT-ensemble.
The van der Waals interactions were cut off at 1.0 nm and a
dispersion correction was applied to energy and pressure. Elec-
trostatic interactions were treated using the smooth Particle
Mesh Ewaldmethod (49, 50), where the real space contribution
was cut off at 1.0 nm and the reciprocal energy term obtained in
k-space was calculated on a grid with 0.12 nm spacing using 4th
order B-splines for interpolation. The Verlet cut-off scheme
was used to generate a pair-list with buffering using a tolerance
of 0.005 kJ/mol/ps for pair-interactions per particle. All bonds
involving hydrogens were constrained with the LINCS algo-
rithm (51), allowing for a time step of 2 fs (only in the NVT
equilibration a shorter time step of 1 fs was used). Temperature
was maintained at constant physiological 310 K using the Bussi
thermostat (52)with a coupling constant of 0.1 ps. In all isobaric
simulations a barostat was coupled to the system in a semi-
isotropic manner to maintain a pressure of 1 bar with a 1-ps
coupling constant and the isothermal compressibility set to
4.5 105 bar1. The Berendsen barostat (53) was used in the
NPT equilibration runs and the Parrinello-Rahmann barostat
(54) for production runs.
Heterologous Expression in Human Embryonic Kidney Cells—
Human embryonic kidney 293 cells (HEK 293) (from Amer-
ican Type Culture Collection) were grown at 37 °C in a hu-
midified 95% air, 5% CO2 incubator in Dulbecco’s modified
Eagle’s medium (DMEM; Gibco) supplemented with 10% (v/v)
heat-inactivated fetal bovine serum, 100 units/ml of penicillin
G, 100g/ml of streptomycin sulfate, and 2mM L-glutamine (all
from Invitrogen). Cells were passaged after reaching 70–80%
confluence, every 2–3 days, up to 30 times.
Cells were plated on poly-L-lysine-coated glass coverslips
(Sigma and VWR, respectively) in 35-mm culture dishes (Sci-
entific Laboratory Supplies, SLS) containing 2 ml of DMEM,
and were then transfected by the calcium phosphate-precip-
itation method (55) with pcDNA3.1 plasmids, one coding for
the human glycine receptor subunit 1 (GenBankTM number
P23415) and one coding for the enhanced green fluorescent
protein (eGFP) to allow detection of transfected cells. In addi-
tion to that, empty pcDNA3.1 plasmid was added to ensure
optimum expression levels. The proportion of empty plasmid
varied depending on the channel expressed. Forwild type chan-
nels, the final DNAmixture contained 2% GlyR 1 cDNA, 18%
eGFP cDNA, and 80% empty pcDNA3.1 plasmid. The total
amount of final DNAmixture was 3 g/plate. The transfection
medium was washed off and replaced by fresh DMEM 4 h after
transfection. Electrophysiological experimentswere performed
1–2 days after transfection.
Pointmutationswere introduced using theQuikChange site-
directed mutagenesis kit (Stratagene). Mutant sequences were
confirmed by sequencing of the full open reading frame by
Source BioScience LifeSciences (Nottingham, UK).
Whole Cell Recordings—These were obtained at least 24 h
after transfection. Patch-pipettes were pulled from thick-
walled borosilicate glass (GC150F; Harvard Apparatus, Eden-
bridge, UK) with a Sutter P-97 pipette puller (Sutter Instru-
ments Co.) and fire-polished to a resistance of 3–5 M	 when
filled with internal solution containing (in mM): 101.1 potas-
sium gluconate, 11 EGTA, 1 CaCl2, 1 MgCl2, 10 HEPES, 20
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tetraethylammoniumchloride (TEA-Cl), 2MgATP, 40 glucose,
and 6 KCl; the pHwas adjusted to 7.4 with NaOH. All solutions
were filtered through a 0.2-m Cyclopore track-etched mem-
brane (GE Healthcare UK Ltd., Little Chalfont, UK) to remove
impurities. The access resistance was below 10 M	 and com-
pensated by at least 70%. The bath solution contained (in mM):
20 Na gluconate, 112.7 NaCl, 2 KCl, 2 CaCl2, 1.2 MgCl2, 10
HEPES, 10 TEA-Cl, and 30 glucose; the pH was adjusted to 7.4
with NaOH.Whole cell currents were elicited by agonist appli-
cation via U-tube application (56) and were recorded at a nom-
inal holding potential of 50 mV with an AxoPatch 200B
amplifier (Molecular Devices). The actual holding potential,
corrected for the junction potential of 11 mV (calculated in
pClamp10; Molecular Devices), was61 mV. Recordings were
prefiltered at 5 kHz with a four-pole low-pass Bessel filter, dig-
itized at sampling rate of 20 kHz with a Digidata 1322A, and
stored directly on a computer hard drive via Clampex10.2 soft-
ware (all Molecular Devices).
TheU-tube positionwas optimized before the experiment by
the application of diluted bath solution (e.g. 50:50, bath solu-
tion:water) to an open tipped recording pipette, until the
10–90% exchange time was better than 100 ms. Average
exchange time was less than 50 ms. A full concentration-re-
sponse curve was obtained in each cell. To monitor the run-
down/up of responses during recording, a standard concentra-
tion of agonist (usually saturating concentration) was applied
every third or fourth response. Only cells in which rundown
was less than 30% were accepted for further analysis and no
correction for rundown was applied. The Hill equation was fit-
ted to each individual concentration-response curve (program
CVFIT; https://github.com/DCPROGS), to estimate EC50 and
nH values. For the purpose of display only, responses were then
normalized to the fitted maximum in each cell. These normal-
ized responses were pooled and refitted with the Hill equation
for the display.
Single-channel Recordings—These were obtained in the cell-
attached configuration at least 24 h after transfection. Extra-
cellular solution was made with HPLC-grade water, filtered
through a 0.2-m Cyclopore track-etched membrane (GE
Healthcare UK Ltd., Little Chalfont, UK) and contained (mM):
102.7 sodium gluconate, 4.7 KCl, 2 CaCl2, 1.2 MgCl2, 10
HEPES, 14 glucose, 15 sucrose, 20TEA-Cl (fromSigma); the pH
was adjusted to 7.4 with NaOH; osmolarity at 320 mOsm. Syl-
gard-coated thick-walled borosilicate pipettes fire-polished to a
resistance of 10–15 M	 were filled with extracellular solution
containing a saturating concentration of agonist. Patches were
voltage-clamped at a pipette potential of 100 mV with an
Axopatch 200B amplifier. Data were pre-filtered at 10 kHzwith
the amplifier four-pole Bessel filter, digitized at 100 kHz with a
Digidata 1322A and Clampex 10.2 (Molecular Devices) directly
on the computer hard drive. Data were digitally filtered (low-
pass Gaussian filter) to a final cut-off frequency of 4–6 kHz.
At high agonist concentrations openings occurred in clusters
delimited by long closed (desensitized) intervals (see Fig. 2B).
Clusters are likely to originate from the activity of a single ion
channel molecule and were used for Popen measurements (57),
selecting clusters longer than 100 ms and with more than 10
openings. First, channel activity in the selected clusters was
idealized by half-amplitude threshold method (Clampfit 10.2,
Molecular Devices). Open probability was calculated as the
ratio of cluster open time over total cluster length. The single-
channel current amplitude was calculated as a difference
between the full open level (at the beginning of each cluster; 0.1
to 10ms stretches) and the baseline (just before each cluster; 10
ms stretches).
The open probability response to a glycine concentration
pulse that approximates synaptic conditions was calculated
assuming an instantaneous rise to 3 mM glycine, followed by an
exponential decay with a time constant of 2.5 ms (13). Rate
constants used in the calculation are those obtained by global
mechanism fit to rat 1 GlyR (28). The effect of the E103K
mutationwas approximated by reducing by 100-fold each of the
three forward rate constants for flipping (1, 2, and 3). The
resulting GlyR would have a maximum Popen of 0.75 and an
EC50 of 1.15 mM (cf. 0.73 and 0.71 mM measured for the E103K
GlyR). Calculations were done using SCALCS. A Jupyter note-
book with calculations is deposited in the SCALCS Git reposi-
tory (https://github.com/DCPROGS/SCALCS/blob/master/
notebooks/Calculate_Popen_SynapticCurrent_alpha1GlyR_Flip.
ipynb). All electrophysiological recordings were carried out at a
temperature of 19–21 °C.
Sarcosine was tested at 100mM for glycine contamination by
an HPLC assay: samples were resuspended in 10 l of 50%
EtOH and reacted for 30 min with the following reagent: 90%
EtOH:triethylamine:phenylisothiocyanate (7:2:1). They were
then evaporated to dryness at room temperature and redis-
solved in 100 l of 5% acetonitrile in 0.1 M ammonium acetate.
A 150 4.6-mm Hypersil C18 column was used. Molecules of
interest were detected at 254 nm. Sarcosine (Sigma) was found
to be contaminated by about 10 M glycine per 100 mM. Sarco-
sine (approximately 7 g) was therefore purified by re-crystalliz-
ing it three times with 95% ethanol obtaining 2.37 g of purified
compound, whose 1H NMR and elemental analysis were con-
sistent with those expected for sarcosine. The glycine contam-
ination of a 100mM solution of purified sarcosinewas below the
detection limit of the HPLC assay (about 1 M).
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